A new ex vivo method for the study of nasal drops on ciliary function.
Any pharmaceutical nasal preparation should respect the physiological function of the mucociliary transport system and should undergo testing to this effect. An experimental protocol has been developed using the guinea pig in order to assess the effects of commercial nasal drop preparations on mucociliary function. The method presented here consists of applying in vivo the test solution on the nasal respiratory epithelium. After a specified contact time and following rapid sacrifice of the animal, the mucosa is removed; the beating frequency of the cilia is then recorded ex vivo by micro-photo-oscillography. The method is sensitive to compounds known to diminish mucociliary function as sodium mercurothiolate inhibits ciliary movement of the nasal epithelium ex vivo. This inhibition of ciliary movement is long-lasting, although reversible. This method can be used to test the action of intranasally administered pharmaceutical preparations on mucociliary function. Commercially available solutions of the nasal vasoconstrictors tymazoline, fenoxazoline or oxymetazoline do not alter ciliary movement ex vivo at dose levels equal to or greater than those clinically utilized. ATP significantly enhances nasal ciliary frequency in instances where a low basal rate occurred. Thus, this method can be used for the testing of the maintenance of nasal ciliary function in the presence of compounds and preparations which will be applied into the nostrils. The advantages over previous techniques include a closer approach to the therapeutic utilization and the maintained physiological conditions of the mucosa during drug administration.
Levrier
J
J
Synthélabo Recherche (L.E.R.S.), Meudon-La-Forêt, France.
Molon-Noblot
S
S
Duval
D
D
Lloyd
K G
KG
D000255:Adenosine Triphosphate / Q000494:pharmacology; D000281:Administration, Intranasal; D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D002923:Cilia / Q000187:drug effects; D005070:Evans Blue; D006168:Guinea Pigs; D066298:In Vitro Techniques; D008297:Male; D014663:Nasal Decongestants / Q000008:administration & dosage / Q000494:pharmacology; D009297:Nasal Mucosa / Q000166:cytology / Q000187:drug effects*; D013849:Thimerosal / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D014663:Nasal Decongestants; D013849:Thimerosal; D005070:Evans Blue; D000255:Adenosine Triphosphate